Calles et al. reported that KRAS-mutant NSCLC patients with concurrent loss of LKB1 immunohistochemistry (IHC) expression experienced a higher number of metastatic lesions (especially extrathoracic and brain metastases) at the time of tumor diagnosis; however, no significant differences, in terms of OS, were observed in patients whose tumors lost LKB1 IHC expression [59]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.